Results 161 to 170 of about 56,276 (247)

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis. [PDF]

Nat Commun
Kanno A, Kito T, Maeda M, Yamaki S, Amano Y, Shimomura T, Anisimova M, Kanazawa N, Suzuki K, Razai A, Mihara T, Kubo K, Shimada T, Nakamura K, Nomura N, Kondo Y, Okimoto A, Sugiyama A, Park D, Stein I, Petshow S, Vandendoren V, Bilic S, Kazimi R, Eastman V, Snipas SJ, Mitchell M, Maurer M, Jefson M, Lichter J, Yamajuku D, Shirai H, Adachi M, Hoeppner DJ, Kubo S, Zito K, Iizuka T, Flynn P, Matsumoto M.   +38 more
europepmc   +1 more source

First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

Cancer, Volume 131, Issue 13, 1 July 2025.
Abstract Background Indoleamine 2,3‐dioxygenase 1 (IDO1) is a heme‐containing enzyme that degrades tryptophan (Trp) to kynurenine (Kyn), which suppresses effector T cells and reduces antitumor activity. KHK2455 is a long‐acting selective IDO1 inhibitor that blocks the heme component of the IDO holoenzyme.
Timothy A. Yap, Olivier Rixe, Capucine Baldini, Ursa Brown‐Glaberman, Sergey Efuni, David S. Hong, Christophe Massard, Jameel Muzaffar, Andreea Varga, Emrullah Yilmaz, Yuta Ikawa, Lisa H. Shiue, Yi Liu, Matthew W. Hruska, Henry Zhao, Akihiro Tokunaga, Solmaz Sahebjam   +16 more
wiley   +1 more source

T-Cell-Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS-CoV-2 Infection. [PDF]

Adv Sci (Weinh)
Fu W, Zhang W, You Z, Li G, Wang C, Lei C, Zhao J, Hou J, Hu S.   +8 more
europepmc   +1 more source

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 74-79, July 2025.
Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois, Nastya Kassir, Koorosh Korfi, Elizabeth Punnoose, Anjali Vaze, Peter Trask, Pritti Gosai, Jane Fridlyand, Chunze Li   +12 more
wiley   +1 more source

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases. [PDF]

MAbs
Yin T, Ramon A, Greenig M, Sormanni P, D'Adamio L.   +4 more
europepmc   +1 more source

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review. [PDF]

Cells
Yamanaka T, Nishikawa T, Yoshida H.
europepmc   +1 more source

Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets

MedComm, Volume 6, Issue 7, July 2025.
This review provides a comprehensive overview of common autoimmune diseases, details clinical manifestations and summarizes the pathogenesis, including the breakdown of immune tolerance, initiation of autoimmune responses, and their progressive amplification.
Xiaoshuang Song, Hantian Liang, Fang Nan, Wenjing Chen, Junyao Li, Liu He, Yiping Cun, Zhenhong Li, Wei Zhang, Dunfang Zhang   +9 more
wiley   +1 more source

Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH₂Mab-250 in Human Breast Cancer Xenografts. [PDF]

Int J Mol Sci
Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Tanaka T, Kato Y.   +6 more
europepmc   +1 more source

Engineering and Structural Elucidation of a Sac7d‐Derived IgG Fc‐Specific Affitin and Its Application for the Light‐Controlled Affinity Purification of Antibodies

ChemBioChem, Volume 26, Issue 11, June 3, 2025.
An affitin derived from the Sac7d scaffold enables the light‐controlled affinity purification of antibodies under physiological conditions, thus overcoming limitations of protein A chromatography. X‐ray crystallographic analysis and affinity measurements reveal complex formation with Fc at the CH2/CH3 junction, similar to protein A/G and FnRn. Combined
Felix Veitl, Andreas Eichinger, Peter Mayrhofer, Markus R. Anneser, Mauricio Testanera, Kilian Rauscher, Matthias Lenz, Arne Skerra   +7 more
wiley   +1 more source